Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (11-20 of 211) with videos related to

Pageof 22
Sort By:
Annals of Translational Medicine|February 12, 2019
BCMA CAR T-cell therapy arrives for multiple myeloma: a realityShih-Feng Cho, Kenneth C Anderson, Yu-Tzu Tai
Frontiers in Immunology|August 28, 2018
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based ImmunotherapyShih-Feng Cho, Kenneth C Anderson, Yu-Tzu Tai
Frontiers in Immunology|August 28, 2018
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1Yu-Tzu Tai, Shih-Feng Cho, Kenneth C Anderson
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|July 16, 2005
Perspectives for combination therapy to overcome drug-resistant multiple myelomaLaurence Catley, Yu-Tzu Tai, Dharminder Chauhan, et al.
British Journal of Haematology|September 10, 2011
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disordersJooeun Bae, Yu-Tzu Tai, Kenneth C Anderson, et al.
Cancers|December 10, 2021
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple MyelomaShih-Feng Cho, Lijie Xing, Kenneth C Anderson, et al.
Clinical Pharmacology : Advances and Applications|August 26, 2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and SelinexorNisha S Joseph, Yu-Tzu Tai, Kenneth C Anderson, et al.
Expert Opinion on Investigational Drugs|February 22, 2014
Daratumumab granted breakthrough drug statusJacob P Laubach, Yu-Tzu Tai, Paul G Richardson, et al.
Frontiers in Oncology|November 4, 2022
Bispecific antibodies in multiple myeloma treatment: A journey in progressShih-Feng Cho, Tsung-Jang Yeh, Kenneth C Anderson, et al.
Journal of Reconstructive Microsurgery|November 12, 2009
Thalidomide-related vessel thrombosis in microsurgical free tissue transferYu-Tzu Tai, Pai-Chun Yen, Hsin-Han Chen, et al.
Pageof 22

Showing results (11-20 of 211) with videos related to

Sort By:
Pageof 22
Annals of Translational Medicine|February 12, 2019
BCMA CAR T-cell therapy arrives for multiple myeloma: a realityShih-Feng Cho, Kenneth C Anderson, Yu-Tzu Tai
Frontiers in Immunology|August 28, 2018
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based ImmunotherapyShih-Feng Cho, Kenneth C Anderson, Yu-Tzu Tai
Frontiers in Immunology|August 28, 2018
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1Yu-Tzu Tai, Shih-Feng Cho, Kenneth C Anderson
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|July 16, 2005
Perspectives for combination therapy to overcome drug-resistant multiple myelomaLaurence Catley, Yu-Tzu Tai, Dharminder Chauhan, et al.
British Journal of Haematology|September 10, 2011
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disordersJooeun Bae, Yu-Tzu Tai, Kenneth C Anderson, et al.
Cancers|December 10, 2021
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple MyelomaShih-Feng Cho, Lijie Xing, Kenneth C Anderson, et al.
Clinical Pharmacology : Advances and Applications|August 26, 2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and SelinexorNisha S Joseph, Yu-Tzu Tai, Kenneth C Anderson, et al.
Expert Opinion on Investigational Drugs|February 22, 2014
Daratumumab granted breakthrough drug statusJacob P Laubach, Yu-Tzu Tai, Paul G Richardson, et al.
Frontiers in Oncology|November 4, 2022
Bispecific antibodies in multiple myeloma treatment: A journey in progressShih-Feng Cho, Tsung-Jang Yeh, Kenneth C Anderson, et al.
Journal of Reconstructive Microsurgery|November 12, 2009
Thalidomide-related vessel thrombosis in microsurgical free tissue transferYu-Tzu Tai, Pai-Chun Yen, Hsin-Han Chen, et al.
Pageof 22